- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03523026
The Effects of Muscle Training in Coronary Artery Patients With Metabolic Syndrome
The Effects of Peripheral and Respiratory Muscle Training in Coronary Artery Patients With Metabolic Syndrome: A Randomized, Prospective, Double-Blind and Controlled Trial
Study Overview
Status
Conditions
Detailed Description
Metabolic syndrome (MS) is a fatal endocrinopathy that appears with insulin resistance and is associated with systemic disorders such as abdominal obesity, glucose intolerance or diabetes mellitus, dyslipidemia, hypertension and coronary artery disease (CAD). The metabolic syndrome, which is regarded as an important public health problem in the world, shows a global increase.
Studies have showed that increased risk for cardiopulmonary disease is associated with people with metabolic syndrome. In the treatment of cardiopulmonary risk factors, therapeutic lifestyle changes and exercise are recommended in primary care strategy. Exercise training programs have been found to have positive effects on cardiopulmonary and metabolic parameters.It has been shown that respiratory functions are also adversely affected in these patients. In patients with metabolic syndrome, FEV1 and FVC were found to be influenced by decreased respiratory function and restrictive ventilation impairment.
Decreased respiratory functions and physical activity in patients with Metabolic Syndrome accompanied by multifactorial risks and complications will adversely affect quality of life. There are no studies in the literature that investigate the effects of peripheral and respiratory muscle training in patients with Metabolic Syndrome. Therefore, we aimed to investigate the effect of peripheral and respiratory muscle training on respiratory muscle strength, respiratory functions, exercise capacity and quality of life in patients with Metabolic Syndrome. This study also aimed to contribute to the international literature by applying respiratory muscle training in patients with coronary artery disease with metabolic syndrome. In addition, in clinically structured rehabilitation programs, in coronary artery disease patients with metabolic syndrome will be provided with a questioning of the importance of respiratory muscle training.
The study will be planned as prospective, randomized, double blind and controlled. Access to the patients will be provided through an archive of patient records and a screening through the online system of the outpatient clinic. Before and after the training patients' effort tests and biochemical tests will be requested. Evaluations before and after the training will be done by another physiotherapist. The study will be conducted prospectively, randomly, double-blind, and controlled. Patients will be randomized into 3 groups.
NMES and Peripheral Muscle Training Group (n: 20).
IMT and Peripheral Muscle Training Group (n: 20),
Peripheral Muscle Training Group (n = 20).
NMES and Peripheral Muscle Training Group: NMES to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. Peripheral muscle training will also be given. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks.
IMT and Peripheral Muscle Training Group: IMT will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator. Training intensity will set at 30% of the maximum inspiratory pressure. Peripheral muscle training will also be given. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks.
Peripheral Muscle Training Group: Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation three times per week for 6 weeks.
The rehabilitation program duration will be 6 weeks in all groups. Changes in parameters will be analyzed before and after treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Fatih/Istanbul
-
Istanbul, Fatih/Istanbul, Turkey, 34096
- Kıymet Muammer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Stable coronary artery disease with metabolic syndrome diagnosis
- The ejection fraction(EF) = % 40 and EF >% 40,
- Participation to the study will be in a voluntary basis
Exclusion Criteria:
- Over 80 years,
- EF <40% or New York Heart Association (NYHA) class III-IV
- Chronic obstructive pulmonary disease (COPD) and respiratory tract infection,
- Documented diagnosis of pulmonary, neurological,orthopedic, renal, hepatic, gastrointestinal, endocrine, oncologic
- New or suspected thromboembolic events
- Severe refractory hypertension
- Acute myocardial infarction and pulmonary edema in the last 6 months,
- Coronary artery revascularization attempts (percutaneous transluminal coronary angioplasty and coronary artery bypass surgery) and previous valve surgery in the last 6 months,
- Cardiac pacemaker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NMES and Peripheral Muscle Training
Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training NMES frequency will be 30 Hertz and the application time will be 30 minutes.Treatment will be programmed for 3 days per week. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks. |
Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode.
In the first sessions, patients ECG will be checked.
Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides.
The NMES frequency will be at 30 Hertz and the application time will be 30 minutes.
Treatment will be programmed for 3 days per week.
The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current.
The program will continue for 6 weeks.
Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
|
Experimental: IMT and Peripheral Muscle Training
Inspirator Muscle Training (IMT) and Peripheral Muscle Training IMT will be applied 7 days per week, twice a day for 15 minutes. Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week. The program will continue for 6 weeks. |
Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes.
The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.
|
Experimental: Peripheral Muscle Training
Peripheral Muscle Training Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks. |
Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional capacity
Time Frame: Baseline and 6 weeks
|
Change from baseline functional capacity test at 6 weeks.
Functional capacity will be assessed by the 6 minute walking test.
The test will be performed according to American Thoracic Society (ATS) criteria.
Patients will be allowed to rest for 10 minutes before the test.
Heart rate, blood pressure, respiratory frequency, oxygen saturation, fatigue and dyspnea perception will be recorded before and after the test.
Walking distance will be calculated.
|
Baseline and 6 weeks
|
Maximum Inspiratory Pressure (MIP)
Time Frame: Baseline and 6 weeks
|
Change from baseline Maximum Inspiratory Pressure (MIP) at 6 weeks.
Respiratory muscle strength will be measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
The most commonly used method for evaluating respiratory muscles is MIP measurement is a non-invasive technique.
|
Baseline and 6 weeks
|
Maximum Expiratory Pressure (MEP)
Time Frame: Baseline and 6 weeks
|
Change from baseline Maximum Expiratory Pressure (MEP) at 6 weeks.
Respiratory muscle strength will be measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
The most commonly used method for evaluating respiratory muscles is MEP measurement is a non-invasive technique.
|
Baseline and 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Forced Vital Capacity (FVC)
Time Frame: Baseline and 6 weeks
|
Change from baseline Forced Vital Capacity (FVC) in respiratory function test at 6 weeks.
FVC will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
|
Baseline and 6 weeks
|
Forced Expiratory Volume 1 second (FEV1)
Time Frame: Baseline and 6 weeks
|
Change from baseline Forced Expiratory Volume 1 second (FEV1) in respiratory function .
FEV1 will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
|
Baseline and 6 weeks
|
Forced Expiratory Volume 1 second / Forced Vital Capacity (FEV1 / FVC)
Time Frame: Baseline and 6 weeks
|
Change from baseline FEV1 / FVC in respiratory function test at 6 weeks.
FEV1 / FVC will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
|
Baseline and 6 weeks
|
Peak flow rate (PEF)
Time Frame: Baseline and 6 weeks
|
Change from baseline Peak flow rate (PEF) in respiratory function test at 6 weeks.
PEF will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
|
Baseline and 6 weeks
|
Physical Activity
Time Frame: Baseline and 6 weeks
|
Change from baseline physical activity scores at 6 weeks.
International Physical Activity Questionnaire (IPAQ) - Short Form (Turkish version of scale ).This questionnaire assesses, in minutes, the physical activity performed by the volunteers during the period of one week.
The IPAQ considered all activities carried out by the volunteer (e.g.
leisure, sport, exercise, and activities at home or in the garden).
According to the responses, the volunteer is considered very active, active, irregularly active or sedentary, according to the intensity and time of the exercises practiced over the last week.
|
Baseline and 6 weeks
|
Forced Expiratory flow from between 25% to 75% of Vital Capacity (FMF 25-75)
Time Frame: Baseline and 6 weeks
|
Change from baseline Forced Expiratory flow from between 25% to 75% of Vital Capacity . FMF will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. |
Baseline and 6 weeks
|
Dyspnea
Time Frame: Baseline and 6 weeks
|
Change from baseline Dyspnea score of Medical Research Council (MRC) at 6 weeks. It will be evaluated by MRC. |
Baseline and 6 weeks
|
Peripheral muscle strength
Time Frame: Baseline and 6 weeks
|
Change from baseline peripheral muscle strength at 6 weeks.
Lower extremity will be evaluated by 'sit to stand' test.
Upper extremity will be evaluated by 'handgrip test'.
|
Baseline and 6 weeks
|
Maximal exercise capacity
Time Frame: Baseline and 6 weeks
|
Change from baseline treadmill test at 6 weeks.
It will be evaluated by treadmill test.
|
Baseline and 6 weeks
|
Quality of life level
Time Frame: Baseline and 6 weeks
|
Change from baseline quality of life scores at 6 weeks.
Short Form (SF-36) Health Survey (Turkish version of scale) The SF-36 is a 36 item questionnaire that measures eight multi-item dimensions of health: physical functioning (10 items) social functioning (2 items) role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), mental health (5 items), energy/vitality (4 items), pain (2 items), and general health perception (5 items).
For each dimension item scores are coded, summed, and transformed on to a scale from 0 (worst possible health state measured by the questionnaire) to 100 (best possible health state).
|
Baseline and 6 weeks
|
Depression level
Time Frame: Baseline and 6 weeks
|
Change from baseline depression scores at 6 weeks.
Beck Depression questionnaire will be administered.
The Beck Depression Questionnaire is an assessment scale that determines the risk of depression and the level of depressive symptoms and the measure of change in severity.
It consists of 21 items.
It provides 4 types of measurements.
Each question contains 4 options.
Each item gets a progressive score between 0-3 and the total score is obtained by their aggregation.
The total varies from 0 to 63 points.
Higher scores indicate higher depression.
|
Baseline and 6 weeks
|
Evaluation of sleep quality
Time Frame: Baseline and 6 weeks
|
Change from baseline evaluation of sleep quality scores at 6 weeks.The Pittsburgh Sleep Quality Index (PSQI) assess sleep quality.
It consists of seven subscales: subjective sleep efficiency, sleep latency, sleep duration, sleep quality, sleep disturbance, sleep medication use, and daytime dysfunction due to sleepiness.
Subscales yield a score from 0 to 3 and PSQI total score of >5 is indicative of poor sleep.
|
Baseline and 6 weeks
|
Anthropometric measurements
Time Frame: Baseline and 6 weeks
|
Change from baseline anthropometric measurements at 6 weeks.
Waist, hip and abdominal circumference measurements will be assessed.The skinfold thickness will be measured with the skinfold caliper.
These measurements will be made from specific measurement sites of chest, biceps, triceps, subscapular, abdominal, suprailiac, quadriceps, gastrocnemius.
|
Baseline and 6 weeks
|
Evaluation of fasting blood glucose in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline fasting blood glucose measurements at 6 weeks.
The blood glucose concentration in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of High Density Lipoprotein in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline High Density Lipoprotein measurements at 6 weeks.
The High Density Lipoprotein in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of Low Density Lipoprotein in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline Low Density Lipoprotein measurements at 6 weeks.
The Low Density Lipoprotein in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of triglyceride in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline triglyceride measurements at 6 weeks.
The triglyceride in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of C-Reactive Protein (CRP) in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline C-Reactive Protein (CRP) measurements at 6 weeks.
The C-Reactive Protein (CRP) in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of sedimentation in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline sedimentation measurements at 6 weeks.
The sedimentation in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of Antistreptolysin O (ASO) in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline Antistreptolysin O (ASO) measurements at 6 weeks.
The Antistreptolysin O (ASO) in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of Creatine phosphokinase (CPK) in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline Creatine phosphokinase (CPK) measurements at 6 weeks.
The Creatine phosphokinase (CPK) in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of Thyroid-Stimulating Hormone (TSH) in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline Thyroid-Stimulating Hormone (TSH) measurements at 6 weeks.
The Thyroid-Stimulating Hormone (TSH) in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of Brain Natriuretic Peptide (Pro-BNP) in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline Brain Natriuretic Peptide (Pro-BNP) measurements at 6 weeks.
The Brain Natriuretic Peptide (Pro-BNP) in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of complete blood count in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline complete blood count measurements at 6 weeks.
The complete blood count in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of ferritin in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline ferritin measurements at 6 weeks.
The ferritin in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of uric acid in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline uric acid measurements at 6 weeks.
The uric acid in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Evaluation of creatinine in blood biochemistry
Time Frame: Baseline and 6 weeks
|
Change from baseline creatinine measurements at 6 weeks.
The creatinine in blood biochemistry will be assessed.
|
Baseline and 6 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kıymet Muammer, MSc PT, Istanbul University Cardiology Institute, Department of Physiotherapy and Rehabilitation
- Study Director: Fatma Karantay Mutluay, Professor, Medipol University, Health Sciences Faculty, Physiotherapy and Rehabilitation
- Study Chair: Rengin Demir, Professor, Istanbul University Cardiology Institute, Department of Physiotherapy and Rehabilitation,
- Study Chair: Alev Arat Özkan, Professor, Istanbul University Cardiology Institute,Catheter Laboratory
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Disease
- Insulin Resistance
- Hyperinsulinism
- Coronary Disease
- Coronary Artery Disease
- Syndrome
- Metabolic Syndrome
Other Study ID Numbers
- Kıymet Muammer
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Neuromuscular Electrical Stimulation
-
Brooks RehabilitationTerminatedBlepharoptosis | LagophthalmosUnited States
-
University Hospital, BrestRecruitingAsthma | Chronic Obstructive Pulmonary Disease Overlap SyndromeFrance
-
Hacettepe UniversityNot yet recruiting
-
MetroHealth Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedStroke | Hemiparesis | FootdropUnited States
-
University of Sao PauloSuspendedRehabilitation | Critical CareBrazil
-
Research Institute for Complex Problems of Cardiovascular...UnknownHeart Failure | Sarcopenia | Peripheral Artery Disease | Exercise IntoleranceRussian Federation
-
Federal University of Rio Grande do SulEnrolling by invitation
-
University of Texas, El PasoRecruitingObesity | Overweight | Insulin ResistanceUnited States
-
University of PittsburghKing Fahad Specialist Hospital Dammam; Saudi Arabian Cultural MissionCompleted